Academic Journal
SLC35D1 Is Associated with Colorectal Cancer Progression, EMT-Related Phenotypes, and Immune Infiltration.
| Τίτλος: | SLC35D1 Is Associated with Colorectal Cancer Progression, EMT-Related Phenotypes, and Immune Infiltration. |
|---|---|
| Συγγραφείς: | Chang YJ; Graduate Institute of Clinical Medicine, College of Medicine, Taipei Medical University, Taipei 11031, Taiwan.; Center for Precision Medicine and Translational Cancer Research, Department of Medical Research, Taipei Medical University Hospital, Taipei Medical University, Taipei 11031, Taiwan.; Department of Pathology, Wan Fang Hospital, Taipei Medical University, Taipei 116079, Taiwan.; Cell Physiology and Molecular Image Research Center, Wan Fang Hospital, Taipei Medical University, Taipei 116079, Taiwan., Tsai KY; Graduate Institute of Clinical Medicine, College of Medicine, Taipei Medical University, Taipei 11031, Taiwan.; Department of Surgery, School of Medicine, College of Medicine, Taipei Medical University, Taipei 11031, Taiwan.; Division of General Surgery, Department of Surgery, Shuang Ho Hospital, Taipei Medical University, New Taipei City 235041, Taiwan., Zumbi CN; Graduate Institute of Clinical Medicine, College of Medicine, Taipei Medical University, Taipei 11031, Taiwan., Lee CC; Graduate Institute of Clinical Medicine, College of Medicine, Taipei Medical University, Taipei 11031, Taiwan., Prince GMSH; Graduate Institute of Clinical Medicine, College of Medicine, Taipei Medical University, Taipei 11031, Taiwan., Batzorig U; Department of Dermatology, Department of Cellular and Molecular Medicine, UCSD Stem Cell Program, University of California, San Diego, La Jolla, CA 92093, USA., Huang CY; Department of Pathology, Wan Fang Hospital, Taipei Medical University, Taipei 116079, Taiwan.; School of Medicine, National Tsing Hua University, Hsinchu 300044, Taiwan.; Institute of Molecular and Cellular Biology, National Tsing Hua University, Hsinchu 300044, Taiwan., Wei PL; Center for Precision Medicine and Translational Cancer Research, Department of Medical Research, Taipei Medical University Hospital, Taipei Medical University, Taipei 11031, Taiwan.; Department of Surgery, School of Medicine, College of Medicine, Taipei Medical University, Taipei 11031, Taiwan.; Division of Colorectal Surgery, Department of Surgery, Taipei Medical University Hospital, Taipei Medical University, Taipei 11031, Taiwan.; Graduate Institute of Cancer Biology and Drug Discovery, Taipei Medical University, Taipei 11031, Taiwan.; Taipei Cancer Center, Taipei Medical University, Taipei 11031, Taiwan. |
| Πηγή: | International journal of molecular sciences [Int J Mol Sci] 2026 Sep 24; Vol. 27 (19). Date of Electronic Publication: 2026 Sep 24. |
| Τύπος έκδοσης: | Journal Article |
| Γλώσσα: | English |
| Στοιχεία περιοδικού: | Publisher: MDPI Country of Publication: Switzerland NLM ID: 101092791 Publication Model: Electronic Cited Medium: Internet ISSN: 1422-0067 (Electronic) Linking ISSN: 14220067 NLM ISO Abbreviation: Int J Mol Sci Subsets: MEDLINE |
| Imprint Name(s): | Original Publication: Basel, Switzerland : MDPI, [2000- |
| Ιατρικοί όροι (MeSH): | Colorectal Neoplasms*/pathology , Colorectal Neoplasms*/genetics , Colorectal Neoplasms*/immunology , Colorectal Neoplasms*/metabolism , Epithelial-Mesenchymal Transition*/genetics, Cell Proliferation/genetics ; Cell Movement/genetics ; Biomarkers, Tumor/genetics ; Biomarkers, Tumor/metabolism ; Humans ; Gene Expression Regulation, Neoplastic ; Prognosis ; Disease Progression ; Phenotype ; Cell Line, Tumor ; Female |
| Περίληψη: | Colorectal cancer (CRC) is one of the most common malignancies worldwide, and the prognosis of patients with metastatic disease remains poor. Solute carrier proteins participate in diverse cellular processes, yet the biological and clinical relevance of the SLC35D family in CRC remains largely unexplored. This study systematically investigated the expression patterns and clinical significance of SLC35D family members and further evaluated the functional role of SLC35D1 in CRC. Bioinformatic analyses using TCGA and other publicly available datasets and analytical platforms were performed to evaluate the expression patterns and clinical significance of SLC35D family members in CRC. Associations of SLC35D1 expression with patient survival, immune cell infiltration, immune checkpoint markers, and cancer-related transcriptional programs were examined. Loss- and gain-of-function experiments in CRC cells were performed to assess the effects of SLC35D1 on cell proliferation, migration, invasion, and EMT-related phenotypes. SLC35D1 expression was significantly decreased in CRC tissues, SLC35D2 showed a nonsignificant downward trend, and SLC35D3 was significantly increased. Lower SLC35D1 expression was associated with poorer clinical outcomes in the TCGA cohort, although this prognostic association was not reproduced in the independent GSE39582 cohort. Bioinformatic analyses further revealed associations between SLC35D1 expression and immune cell infiltration, immune checkpoint markers, and several cancer-related transcriptional programs. Although the association between SLC35D1 and the EMT-related signature was modest, pathway-enrichment analyses suggested a potential relationship with EMT-related processes. Consistent with these observations, loss- and gain-of-function studies showed that SLC35D1 expression was associated with changes in CRC cell proliferation, migration, invasion, and EMT-related molecular phenotypes. Our findings identify SLC35D1 as an understudied SLC35D family member associated with CRC progression and clinical outcome. Functional studies showed that modulation of SLC35D1 expression was associated with changes in malignant phenotypes in CRC cells, whereas its relationships with EMT-related programs and the tumor immune microenvironment warrant further mechanistic investigation. These findings suggest that SLC35D1 may have prognostic relevance in CRC, although its prognostic value requires further validation in independent clinical cohorts. |
| References: | Cancer. 2019 Dec 1;125(23):4139-4147. (PMID: 31433498) Genomics. 2005 Jan;85(1):106-16. (PMID: 15607426) FEBS Lett. 2008 Nov 12;582(27):3811-6. (PMID: 18948099) Clin Interv Aging. 2016 Jul 19;11:967-76. (PMID: 27486317) Comput Struct Biotechnol J. 2014 Jun 11;10(16):23-32. (PMID: 25210595) Gut. 2014 Feb;63(2):317-25. (PMID: 23408352) Trends Pharmacol Sci. 2019 Oct;40(10):790-800. (PMID: 31519459) Mol Aspects Med. 2013 Apr-Jun;34(2-3):719-34. (PMID: 23506905) Front Immunol. 2020 Sep 18;11:1624. (PMID: 33042104) J Formos Med Assoc. 2020 Dec;119(12):1731-1741. (PMID: 31522970) Cancers (Basel). 2023 Jun 20;15(12):. (PMID: 37370870) BMC Genet. 2020 Feb 22;21(1):20. (PMID: 32087688) Methods Mol Biol. 2011;696:291-303. (PMID: 21063955) Pflugers Arch. 2004 Feb;447(5):768-75. (PMID: 12759756) Clin Cancer Res. 2015 Mar 1;21(5):962-968. (PMID: 25107915) Mol Syst Biol. 2020 Jul;16(7):e9652. (PMID: 32697042) J Cancer. 2021 Jul 13;12(18):5439-5453. (PMID: 34405007) Biosystems. 2015 Jan;127:67-72. (PMID: 25451770) Comput Struct Biotechnol J. 2019 Aug 07;17:1123-1134. (PMID: 31462968) Clin Transl Med. 2021 Mar;11(3):e356. (PMID: 33783998) Am J Clin Pathol. 2017 Feb 03;147(3):221-260. (PMID: 28165529) Cancer Res. 2017 Nov 1;77(21):e108-e110. (PMID: 29092952) JAMA. 2021 Feb 16;325(7):669-685. (PMID: 33591350) Diseases. 2024 Mar 21;12(3):. (PMID: 38534987) Nucleic Acids Res. 2015 Jan;43(Database issue):D447-52. (PMID: 25352553) iScience. 2022 Apr 01;25(5):104193. (PMID: 35479410) Exp Cell Res. 2018 Sep 15;370(2):571-578. (PMID: 30016638) BMC Med Genomics. 2009 Apr 24;2:18. (PMID: 19393097) Oncotarget. 2020 Feb 25;11(8):801-812. (PMID: 32166001) Front Oncol. 2021 Jun 15;11:638099. (PMID: 34211835) Nat Rev Drug Discov. 2017 Mar;16(3):203-222. (PMID: 28209991) Trends Cell Biol. 2022 Mar;32(3):186-201. (PMID: 34511324) Curr Gastroenterol Rep. 2019 Jul 10;21(8):36. (PMID: 31289917) OMICS. 2012 May;16(5):284-7. (PMID: 22455463) Sci Rep. 2020 Apr 30;10(1):7315. (PMID: 32355273) Genome Biol. 2014;15(12):550. (PMID: 25516281) Mol Cancer Res. 2019 Feb;17(2):655-665. (PMID: 30401720) Mol Cancer. 2023 Mar 11;22(1):48. (PMID: 36906534) Cancer Cell. 2012 Mar 20;21(3):309-22. (PMID: 22439926) Cell. 2012 Mar 30;149(1):22-35. (PMID: 22464321) Cell. 2018 Apr 5;173(2):400-416.e11. (PMID: 29625055) Int J Cancer. 2024 Feb 1;154(3):573-584. (PMID: 37700602) Dig Dis Sci. 2015 Mar;60(3):762-72. (PMID: 25492499) BMC Bioinformatics. 2013 Jan 16;14:7. (PMID: 23323831) Mol Cell. 2020 Nov 5;80(3):384-395. (PMID: 32997964) FEBS J. 2019 May;286(10):1815-1837. (PMID: 30637950) Biosci Rep. 2019 May 21;39(5):. (PMID: 30038060) Am J Physiol Cell Physiol. 2022 Jun 1;322(6):C1187-C1200. (PMID: 35385322) Acta Pharm Sin B. 2021 May;11(5):1274-1285. (PMID: 34094833) BMC Med Genomics. 2019 Jul 11;12(Suppl 5):101. (PMID: 31296229) Innovation (Camb). 2024 Apr 09;5(3):100625. (PMID: 38706955) Sci Signal. 2013 Apr 02;6(269):pl1. (PMID: 23550210) Nat Med. 2007 Nov;13(11):1363-7. (PMID: 17952091) Autophagy. 2016 Jul 2;12(7):1168-79. (PMID: 27171858) |
| Grant Information: | 112TMU-SHH-17 Taipei Medical University-Shuang Ho Hospital; NSTC 113-2314-B-038-070-MY1 National Science and Technology Council |
| Contributed Indexing: | Keywords: SLC35D gene family; SLC35D1; colorectal cancer; epithelial–mesenchymal transition (EMT); immune cell infiltration; nucleotide-sugar transporters |
| Substance Nomenclature: | 0 (Biomarkers, Tumor) |
| Entry Date(s): | Date Created: 20261016 Date Completed: 20261016 Latest Revision: 20261020 |
| Update Code: | 20261020 |
| PubMed Central ID: | PMC13664988 |
| DOI: | 10.3390/ijms27198517 |
| PMID: | 42883769 |
| Βάση Δεδομένων: | MEDLINE |
| ISSN: | 1422-0067 |
|---|---|
| DOI: | 10.3390/ijms27198517 |